| Document |
Document Title |
|
WO/2018/138359A1 |
The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of R...
|
|
WO/2018/137959A1 |
The present invention relates to a process for preparing benzylic amides of formula (I) wherein the variables have the meaning as defined in the description, by reductive amidation of a nitrile of formula (II) wherein the variables have ...
|
|
WO/2018/140599A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 ...
|
|
WO/2018/139787A1 |
The present invention relates to a method for purifying phenol, the method comprising the steps of: contacting a phenol stream, which contains hydroxy acetone, 2-methylbenzofuran, 3-methylbenzofuran, and phenol, with an acyl chloride, in...
|
|
WO/2018/133790A1 |
The present disclosure relates to heteroaromatic containing organic compounds and methods of use and preparation thereof. The compounds disclosed herein can be used as organic semiconductors.
|
|
WO/2018/133716A1 |
The present invention provides a heterocyclic urea compound as an indoleamine-2,3-dioxygenase inhibitor, a preparation method thereof, and a use of the heterocyclic urea compound as an indoleamine-2,3-dioxygenase inhibitor or a pharmaceu...
|
|
WO/2018/135798A1 |
The present invention provides a novel heterocyclic compound and an organic light emitting element using the same.
|
|
WO/2018/136792A1 |
The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
|
|
WO/2018/130625A1 |
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...
|
|
WO/2018/132660A1 |
Disclosed herein are inhibitors of the Integrator complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable...
|
|
WO/2018/130865A1 |
A composition for treating headaches and migraines and methods of using same for preventative use to decrease the frequency, duration and severity of headaches and migraines in children and adults.
|
|
WO/2018/130155A1 |
Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a ...
|
|
WO/2018/122454A1 |
Ina method and an apparatus furfuralis recovered from a steam stream (3) which is formed in a treatment of a pretreated wood based material (1).The pretreated wood based material (1) which comprises at least carbohydrates is treated in a...
|
|
WO/2018/121329A1 |
Disclosed are a magnetic metal oxide crosslinked acidic poly(ionic liquid) and the use thereof, wherein same belong to the technical field of solid acid catalysis. The catalyst prepared by the present invention has a good Lewis acidic si...
|
|
WO/2018/124088A1 |
Provided are novel pest control agents, in particular, a bactericide and a nematicide. An alkylphenyl-substituted amide compound represented by formula (I) [wherein: G1 stands for a structure represented by G1-2, G1-3, G1-4, etc.; X1 sta...
|
|
WO/2018/122453A1 |
In a method and an apparatus furfural is separated from a material stream (3) which is formed in a treatment of a pretreated wood based material (1). The material stream (3) which comprises at least furfural is introduced to a separation...
|
|
WO/2018/115421A1 |
The present invention discloses compounds of formula (I) that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
|
|
WO/2018/114534A1 |
The present invention relates to a method for production of a fuel composition, more specifically a middle distillate fuel composition, and a composition - in particular a co feed composition comprising a furanyl containing oligomerisati...
|
|
WO/2018/113599A1 |
The present invention concerns a process for preparing a tetrahydrofuran compound comprising at least two amine functional groups by reacting a furan compound comprising at least two nitrogen-containing functional groups with hydrogen in...
|
|
WO/2018/116081A1 |
Certain embodiments are directed to an integrated process for the production of Maleic Anhydride (MAN), 1,4 Butanediol (BDO), Gamma-ButyroLactone (GBL), and PolyButylene Terephthalate (PBT) utilizing NC4 rich stream from a recycle stream...
|
|
WO/2018/113785A1 |
Provided are a polymer containing a furan crosslinking group and the use thereof in an organic electronic device. Provided is a polymer containing a furan crosslinking group, having the following general formula (I): wherein x and y resp...
|
|
WO/2018/117152A1 |
The purpose of the present invention is to provide: a method for producing a 7H-pyrrolo[2,3-d]pyrimidine derivative which is useful as a Janus kinase (JAK) inhibitory agent; an intermediate of the same; and a method for producing the int...
|
|
WO/2018/117493A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising the same. According to the present invention, the compound is used in an organic material layer, preferably in a light-emitting layer, ...
|
|
WO/2018/109781A1 |
The present invention provides an improved process for preparation of Firocoxib of Formula I. Further, the present invention relates to novel process for the preparation of crystalline polymorphic form B of Firocoxib of Formula I.
|
|
WO/2018/110887A1 |
The present invention provides a heterocyclic compound having a novel structure, and an organic light-emitting element comprising the heterocyclic compound.
|
|
WO/2018/104856A1 |
A process of obtaining a purified geometric isomer of an unsaturated macrocyclic compound is disclosed herein. The process is effected by contacting an ion exchange medium comprising silver ions with a mixture comprising at least one geo...
|
|
WO/2018/104305A1 |
Substituted aromatic sulfonamides of formula (I) which are antagonists or negative allosteric modulators of P2X4, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a ph...
|
|
WO/2018/104295A1 |
Disclosed are sulfonamide analogues of galiellactone of formula (I) as STAT3-inhibitors for use in the treatment of a STAT3 signaling related disorder, e.g. solid cancers, hematological cancers, benign tumors, hyperproliferative diseases...
|
|
WO/2018/102427A1 |
Provided herein are methods of preparation of I by reacting i with acid where R1 and R2 are each independently a leaving group. Intermediates to make i are also claimed.
|
|
WO/2018/099432A1 |
The present invention relates to a fused ring compound and a preparation method and application thereof. The fused ring compound is represented by general formula (I). The fused ring compound emits fluorescence at a short wavelength, and...
|
|
WO/2018/100184A1 |
The invention relates to a method for producing 5-hydroxymethylfurfural (HMF) in a continuous process, which leads to the obtainment of an HMF fraction, a carbohydrate/acid fraction, a fructose fraction, and a levulinic-acid and formic-a...
|
|
WO/2018/100016A1 |
The present invention relates to 1-fluorocyclohexyl-methoxy-aryl compounds of formula (I), in which R1, R2, A1, A2, m and n are defined as indicated in claim 1, to their production, to their use as components in liquid crystal media and ...
|
|
WO/2018/101329A1 |
The purpose of the present invention is to develop a therapeutic agent for inflammatory diseases such as inflammatory bowel disease and NASH, said therapeutic agent having few adverse effects and high efficacy. The present invention prov...
|
|
WO/2018/100515A1 |
The invention relates to novel ruthenium complexes of formula (9). The invention also relates to the method for preparation of novel metal complexes of formula (9) and their use in olefin metathesis reactions.
|
|
WO/2018/098831A1 |
Provided are a biomass-based epoxy resin and method for preparation thereof; under conditions of N,N-dimethylformamide as a catalyst, 2,5-furandicarboxylic acid and thionyl chloride are acylated to obtain 2,5-furan diformyl chloride; the...
|
|
WO/2018/094487A1 |
The present invention relates to the process of enzymatic epoxidation of terpenes using lipase and hydrogen peroxide, to epoxidized compounds and to the use of the compounds as an antiproliferative agent. Enzymatic epoxidation was carrie...
|
|
WO/2018/097654A2 |
The present specification provides a coating composition comprising a fluorene derivative, an organic light emitting device formed by using the coating composition, and a method for manufacturing the same.
|
|
WO/2018/095287A1 |
Disclosed are a benzoheterocyclyl alkylamine compound, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a preparation method therefor, and a use of the same for preparing antibacterial medicines as an inhibit...
|
|
WO/2018/095940A1 |
The present invention relates to Bisbenzofuran-fused indeno[1,2-b]fluorene derivatives and related compounds as materials for organic electroluminescent devices (OLEDs).
|
|
WO/2018/095888A1 |
The present invention relates to bisbenzofuran-fused 2,8-diaminoindeno[1,2-b]fluorene derivatives and related compounds of formula (1) as materials for organic electroluminescent devices (OLEDs).
|
|
WO/2018/096401A1 |
The present invention provides a compound useful as a novel antitumor agent targeting a CSC that is important in continuous proliferation of malignant tumor, metastasis and recurrence of cancer, and its resistance to an antitumor agent; ...
|
|
WO/2018/097725A1 |
A process for treating a furan-2,5-dicarboxylic acid composition, which process comprises: introducing a furan-2,5-dicarboxylic acid composition, which furan-2,5-dicarboxylic acid composition contains an impurity compound and which impur...
|
|
WO/2018/097726A1 |
A process for treating a dicarboxylic acid composition, with the proviso that the dicarboxylic acid is not furan 2,5-dicarboxylic acid, which process comprises: - introducing a dicarboxylic acid composition, which dicarboxylic acid compo...
|
|
WO/2018/097944A1 |
Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions...
|
|
WO/2018/093080A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2018/090149A1 |
The present invention describes slow-release compositions for the effective delivery of active ingredients such as putrescine and Vitamin C into the skin. These compositions may be used in a variety of cosmetic and therapeutic applicatio...
|
|
WO/2018/093015A1 |
The present invention provides an organic light-emitting device having an improved driving voltage, efficiency, and lifespan.
|
|
WO/2018/093413A1 |
A method for preparing sugar-based mono and diesters is described. The process entails the esterification of 2,5-furan-dicarboxylic acid (FDCA) with an alcohol in the presence of low loadings of a homogeneous organotin (IV) catalyst.
|
|
WO/2018/094334A1 |
Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
|
|
WO/2018/093818A1 |
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
|
